sj-7z-4-ipe-10.1177_20416695231209846 - Supplemental material for Eyes can tell: Assessment of implicit attitudes toward AI art

Supplemental material, sj-7z-4-ipe-10.1177_20416695231209846 for Eyes can tell: Assessment of implicit attitudes toward AI art by Yizhen Zhou and Hideaki Kawabata in i-Perception</p

sj-csv-1-ipe-10.1177_20416695231209846 - Supplemental material for Eyes can tell: Assessment of implicit attitudes toward AI art

Supplemental material, sj-csv-1-ipe-10.1177_20416695231209846 for Eyes can tell: Assessment of implicit attitudes toward AI art by Yizhen Zhou and Hideaki Kawabata in i-Perception</p

sj-csv-3-ipe-10.1177_20416695231209846 - Supplemental material for Eyes can tell: Assessment of implicit attitudes toward AI art

Supplemental material, sj-csv-3-ipe-10.1177_20416695231209846 for Eyes can tell: Assessment of implicit attitudes toward AI art by Yizhen Zhou and Hideaki Kawabata in i-Perception</p

sj-csv-2-ipe-10.1177_20416695231209846 - Supplemental material for Eyes can tell: Assessment of implicit attitudes toward AI art

Supplemental material, sj-csv-2-ipe-10.1177_20416695231209846 for Eyes can tell: Assessment of implicit attitudes toward AI art by Yizhen Zhou and Hideaki Kawabata in i-Perception</p

Comparison of tumor volume reduction in TNBC patients between iNOS expression decreased group and iNOS expression increased and positively remained unchanged group after neoadjuvant chemotherapy.

<p>Asterisk indicates p<0.01.</p

Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy

<div><p>Triple-negative breast cancer is a high-risk breast cancer with poor survival rate. To date, there is a lack of targeted therapy for this type of cancer. One unique phenomenon is that inflammatory breast cancer is frequently triple negative. However, it is still ambiguous how inflammation influences triple-negative breast cancer growth and responding to chemotherapy. Herein, we investigated the levels of inflammation-associated enzyme, iNOS, in 20 triple-negative breast cancer patients’ tumors, and examined its correlation with patients’ responses to platinum-based neoadjuvant chemotherapy. Our studies showed that triple-negative breast cancer patients with attenuated iNOS levels in tumor cells after treatment showed better responses to platinum-based neoadjuvant chemotherapy than other triple-negative breast cancer patients. Our further <i>in vitro</i> studies confirmed that induction of proper levels of NO increased the resistance to cisplatin in triple-negative MDA-MB-231 cells. Our data suggest that aberrant high level of iNOS/NO are associated with less effectiveness of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer. Therefore, we propose to monitor iNOS levels as a new predictor for triple-negative breast cancer patient’s response to platinum-based neoadjuvant chemotherapy. Moreover, iNOS/NO is considered as a potential target for combination therapy with platinum drugs for triple-negative breast cancer.</p></div

Treatment of MDA-MB-231 cells with DETA NONOate results in a increase of growth, MTT assay was performed after 72-hour treatment.

<p>Treatment of MDA-MB-231 cells with DETA NONOate results in a increase of growth, MTT assay was performed after 72-hour treatment.</p

Analysis of iNOS protein levels in TNBC patients by immunoblotting.

<p>Analysis of iNOS protein levels in TNBC patients by immunoblotting.</p

Detection of iNOS protein levels in TNBC tissues by immunohistochemistry.

<p>Top panel: demonstration of iNOS levels in patient’s tumor changing from positive to negative after treatment in IDC. Bottom panel: demonstration of iNOS levels in patient’s tumor changing from negative to positive after treatment in ILC.</p

The presence of DETA NONOate reverse the inhibitory effect of cisplatin on MDA-MB-231 cells.

<p>Asterisk indicates p<0.01.</p